Home › Lung Cancer › Ohio › Columbus
Lung Cancer clinical trials in Columbus, OH
37 studies for Lung Cancer are looking for participants at sites in and around Columbus (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RecruitingPhase 3
- Mount Carmel East Hospital, Columbus
- The Mark H Zangmeister Center, Columbus
- Mount Carmel Health Center West, Columbus
- and 3 more
Prospective Multiomic Analysis in Small-Cell Lung Cancer
RecruitingObservational study
- Ohio State University Comprehensive Cancer Center, Columbus
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- Ohio State University Comprehensive Cancer Center, Columbus
- Mount Carmel East Hospital, Columbus
- The Mark H Zangmeister Center, Columbus
- and 8 more
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
RecruitingPhase 3
- Ohio State University Comprehensive Cancer Center, Columbus
- The Mark H Zangmeister Center, Columbus
- Mount Carmel Grove City Hospital, Grove City · 7 mi away
- and 1 more
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
RecruitingPhase 3
- Columbus Oncology and Hematology Associates Inc, Columbus
- Grant Medical Center, Columbus
- The Mark H Zangmeister Center, Columbus
- and 3 more
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RecruitingPhase 3
- Ohio State University Comprehensive Cancer Center, Columbus
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
RecruitingPhase 3
- The Ohio State University, Columbus
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
RecruitingPhase 1/2
- Local Institution - 0102, Columbus
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
RecruitingPhase 2/3
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RecruitingPhase 2/3
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C, Columbus
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
RecruitingPhase 1/2
- Ohio State University Comprehensive Cancer Center, Columbus
Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
RecruitingPhase 1
- Ohio State University Comprehensive Cancer Center, Columbus
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RecruitingPhase 3
- Ohio State University, Columbus
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RecruitingPhase 3
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T, Columbus
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
- Ohio State University Hospital, Columbus
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
RecruitingPhase 1/2
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
RecruitingPhase 1
- The Ohio State University (OSU) Wexner Medical Center, Columbus
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
RecruitingPhase 3
- Ohio State University Hospitals, Columbus
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
RecruitingPhase 3
- Ohio State University Comprehensive Cancer Center, Columbus
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
RecruitingPhase 3
- Riverside Methodist Hospital, Columbus
- Grant Medical Center, Columbus
- Doctors Hospital, Columbus
- and 3 more
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
RecruitingPhase 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
RecruitingPhase 1
- Xencor Investigative Site, Columbus
Evaluation of Geriatric Assessment and Management for Older Adults With Non-small Cell Lung Cancer Receiving Chemotherapy Radiation Therapy
RecruitingHealthy volunteers welcome
- Ohio State University Comprehensive Cancer Center, Columbus
Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer
RecruitingPhase 1
- Ohio State University Comprehensive Cancer Center, Columbus
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
RecruitingPhase 2
- Ohio State University Comprehensive Cancer Center, Columbus
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
RecruitingPhase 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RecruitingPhase 2
- Mount Carmel East Hospital, Columbus
- The Mark H Zangmeister Center, Columbus
- Mount Carmel Grove City Hospital, Grove City · 7 mi away
- and 2 more
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
RecruitingPhase 1/2
- The Ohio State University Wexner Medical Center, Columbus
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RecruitingPhase 2
- Ohio State University Comprehensive Cancer Center, Columbus
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RecruitingPhase 2/3
- Columbus Oncology and Hematology Associates Inc, Columbus
- Riverside Methodist Hospital, Columbus
- Grant Medical Center, Columbus
- and 7 more
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RecruitingPhase 1/2
- Ohio State University Comprehensive Cancer Center, Columbus
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
RecruitingPhase 2
- Ohio State University Comprehensive Cancer Center, Columbus
Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
RecruitingPhase 1/2
- Ohio State University Comprehensive Cancer Center, Columbus
Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers
RecruitingHealthy volunteers welcome
- Ohio State University, Columbus
PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
RecruitingPhase 1
- Ohio State University Comprehensive Cancer Center, Columbus
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Columbus
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
RecruitingPhase 1/2
- The Ohio State University, Columbus
About Lung Cancer
Lung cancer forms in tissues of the lung, usually in the cells that line the air passages. It is the leading cause of cancer death in both men and women.
More about Lung Cancer on MedlinePlus
Lung Cancer trials in other cities
- Houston, TX78 studies
- Boston, MA62 studies
- New York City, NY60 studies
- Los Angeles, CA45 studies
- Arlington, VA41 studies
- Washington, DC41 studies
- Chicago, IL41 studies
- Nashville, TN40 studies
- Baltimore, MD40 studies
- St. Louis, MO39 studies
- Philadelphia, PA36 studies
- Seattle, WA33 studies
Other studies in Columbus
- Non-Small Cell Lung Cancer56 studies
- Breast Cancer39 studies
- Ovarian Cancer39 studies
- Cancer (all types)38 studies
- Acute Myeloid Leukemia35 studies
- Chronic Lymphocytic Leukemia28 studies
- Metastatic Cancer27 studies
- Endometrial Cancer25 studies
- Colorectal Cancer24 studies
- Prostate Cancer24 studies
- Multiple Myeloma24 studies
- Melanoma21 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.